title: [Neuroleptic malignant syndrome in a patient treated with alimemazine].
authors.forename: Marine
authors.initials: M
authors.lastname: Auffret
authors.forename: Johana
authors.initials: J
authors.lastname: Béné
authors.forename: Marie
authors.initials: M
authors.lastname: Lachatre
authors.forename: Marc
authors.initials: M
authors.lastname: Lambert
authors.forename: Sophie
authors.initials: S
authors.lastname: Gautier
mesh_terms: D000082:Acetaminophen / Q000627:therapeutic use; D000368:Aged; D015415:Biomarkers; D003221:Confusion / Q000139:chemically induced; D003402:Creatine Kinase / Q000097:blood; D004630:Emergencies; D005334:Fever / Q000139:chemically induced / Q000188:drug therapy; D006801:Humans; D006993:Hypnotics and Sedatives / Q000009:adverse effects* / Q000737:chemistry / Q000627:therapeutic use; D007770:L-Lactate Dehydrogenase / Q000097:blood; D008297:Male; D009459:Neuroleptic Malignant Syndrome / Q000097:blood / Q000188:drug therapy / Q000209:etiology* / Q000523:psychology; D007319:Sleep Initiation and Maintenance Disorders / Q000188:drug therapy; D014291:Trimeprazine / Q000009:adverse effects* / Q000737:chemistry / Q000627:therapeutic use
chemical_list: D015415:Biomarkers; D006993:Hypnotics and Sedatives; D000082:Acetaminophen; D014291:Trimeprazine; D007770:L-Lactate Dehydrogenase; D003402:Creatine Kinase